# Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
Canonical URL: https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-fri-42a5b003
Ticker: LRMR
Company: Larimar Therapeutics
Source: Larimar Therapeutics
Published: 2026-06-26 20:05 EST
Original Source URL: https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-announces-investor-event-nomlabofusp
## Summary

Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an

## Article Body
Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an
## Recent Company News
- 2026-06-29 10:30 EST — [Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-positive-open-label-data-and-submission-of-first-mo-5e1889f2) — Source: Larimar Therapeutics
- 2026-06-26 20:05 EST — [Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-investor-event-on-the-nomlabofusp-program-for-fri-42a5b003) — Source: Larimar Therapeutics
- 2026-06-25 13:46 EST — [Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2026-financial-and-business-update) — Source: Larimar Therapeutics
- 2026-06-25 13:46 EST — [Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-conference-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreich-s-ataxia) — Source: Larimar Therapeutics
- 2026-06-25 13:46 EST — [Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-positive-data-from-ongoing-long-term-open-label-study-and-updates-to-nomlabofusp-program-for-friedreich-s-ataxia) — Source: Larimar Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)